Krajina: Austrália
Jazyk: angličtina
Zdroj: Department of Health (Therapeutic Goods Administration)
Gliclazide
Apotex Pty Ltd
Medicine Registered
APO-GLICLAZIDE MR _30 MG TABLETS_ _Modified Release tablets containing the active ingredient gliclazide_ CONSUMER MEDICINE INFORMATION _FOR A COPY OF A LARGE PRINT LEAFLET, PH: 1800 195 055_ WHAT IS IN THIS LEAFLET READ THIS LEAFLET CAREFULLY BEFORE TAKING YOUR MEDICINE. This leaflet answers some common questions about gliclazide. It does not contain all the available information. It does not take the place of talking to your doctor, pharmacist or diabetes educator. The information in this leaflet was last updated on the date listed on the last page. More recent information on this medicine may be available. ASK YOUR DOCTOR OR PHARMACIST: • if there is anything you do not understand in this leaflet • if you are worried about taking your medicine, or • to obtain the most up-to-date information. All medicines have risks and benefits. Your doctor has weighed the risks of you using this medicine against the benefits they expect it will have for you. Pharmaceutical companies cannot give you medical advice or an individual diagnosis. Keep this leaflet with your medicine. You may want to read it again. WHAT THIS MEDICINE IS USED FOR The name of your medicine is APO- Gliclazide MR. It contains the active ingredient gliclazide. The tablets release the gliclazide gradually over 24 hours. The medicine is used to control, blood glucose in patients with Type II diabetes mellitus. This type of diabetes is also known as non-insulin-dependent diabetes mellitus (NIDDM) or maturity onset diabetes. Gliclazide is used when diet and exercise are not enough to control your blood glucose. Gliclazide can be used alone, or together with other medicines for treating diabetes Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed this medicine for another reason. This medicine is available only with a doctor's prescription. _HOW IT WORKS_ Gliclazide belongs to a group of medicines called the sulfonylureas. Gliclazide lowers high blood glucose b Prečítajte si celý dokument
Product Information – Australia APO-Gliclazide MR Tablets Page 1/9 APO-GLICLAZIDE MR 30 MG TABLETS NAME OF THE MEDICINE Gliclazide CHEMICAL NAME : 1-(3-azabicyclo[3.3.0]oct-3-yl)-3-_p_-tolylsulphonylurea. CHEMICAL STRUCTURE : MOLECULAR FORMULA : C 15 H 21 N 3 O 3 S MOLECULAR WEIGHT : 323.4 CAS REGISTRY NUMBER : 21187-98-4 DESCRIPTION Gliclazide is a white or almost white powder which is practically insoluble in water. Freely soluble in dichloromethane, sparingly soluble in acetone and slightly soluble in ethanol 96%. The melting point of gliclazide is approximately 168°C. Gliclazide MR 30 mg tablets are intended for oral administration. Each tablet contains gliclazide 30 mg. They are white to off-white, flat faced, beveled edge, capsule shaped tablets, engraved “APO 30” on one side and plain on the other side. In addition to gliclazide, each tablet contains the following inactive ingredients: hypromellose, stearic acid and silica, colloidal anhydrous. PHARMACOLOGY Gliclazide is an oral hypoglycaemic sulfonylurea which differs from other related compounds. It has an N-containing heterocyclic ring with an endocyclic bond. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the beta-cells of the Islets of Langerhans. Gliclazide shows high affinity, strong selectivity and reversible bin ding to the β- cell KATP channels with a low affinity for cardiac and vascular KATP channels. Increased postprandial insulin and C-peptide secretion persists after two years of treatment. Gliclazide also has extra-pancreatic effects and haemovascular properties. Effects on insulin release In type II diabetes, gliclazide restores the first peak of insulin secretion in response to glucose and increases Prečítajte si celý dokument